Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.45 |
| ▸ | NPY1R | P25929 | 6/20 | 0.45 |
| ▸ | NPY2R | P49146 | 4/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.45 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.41 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7850288 | 0.99 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL7549487 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RMETAP2 | |
| SCHEMBL11099634 | 0.87 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL8512961 | 0.87 | MCHR1 (0.42) | NPY4RNPY1RNPY2RNPY5RMETAP2 | |
| Hydrochloric Acid SCHEMBL11208857 | 0.86 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| Pabetan SCHEMBL29894618 | 0.85 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| Pabetan SCHEMBL21571465 | 0.85 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| Pabetan SCHEMBL14928984 | 0.85 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| Pabetan SCHEMBL4546522 | 0.85 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL8515668 | 0.85 | HDAC1 (0.45) | NPY4RNPY1RNPY2RNPY5RMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10876058-B2 | Method for prevention of biodeterioration of fuels | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2020-12-29 | — | — | US | claimed |
| US-10876059-B2 | Method for prevention of biodeterioration of fuels | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2020-12-29 | — | — | US | claimed |
| US-20170260467-A1 | METHOD FOR PREVENTION OF BIODETERIORATION OF FUELS | GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2017-09-14 | — | — | US | claimed |
| US-20030171317-A1 | Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solvents | TRUSTEES OF TUFTS COLLEGE | 2003-09-11 | — | — | US | claimed |
| EP-1077718-B1 | ENHANCEMENT OF OXAZOLIDINONE ANTIBACTERIAL AGENTS ACTIVITY BY ARGININE DERIVATIVES | UPJOHN CO (US) | 2002-08-14 | — | — | EP | claimed |
| EP-1019076-A4 | METHODS AND COMPOSITIONS FOR REDUCING BACTERIAL TOLERANCE OF DISINFECTANTS AND ORGANIC SOLVENTS | TUFTS COLLEGE (US) | 2002-01-23 | — | — | EP | claimed |
| EP-1019076-A1 | METHODS AND COMPOSITIONS FOR REDUCING BACTERIAL TOLERANCE OF DISINFECTANTS AND ORGANIC SOLVENTS | TRUSTEES OF TUFTS COLLEGE (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1999017607-A2 | METHODS AND COMPOSITIONS FOR REDUCING BACTERIAL TOLERANCE OF DISINFECTANTS AND ORGANIC SOLVENTS | TRUSTEES OF TUFTS COLLEGE (US) | 1999-04-15 | — | — | WO | claimed |
| WO-1999017791-A1 | METHODS AND COMPOSITIONS FOR REDUCING BACTERIAL TOLERANCE OF DISINFECTANTS AND ORGANIC SOLVENTS | TRUSTEES OF TUFTS COLLEGE (US) | 1999-04-15 | — | — | WO | claimed |
| US-12035710-B2 | Aqueous hop extracts and their use as antimicrobial agents | Nature Recombined Sciences Inc. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-11969476-B2 | Antibody molecule-drug conjugates and uses thereof | Visterra, Inc. (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3374391-B1 | ANTIBODY MOLECULE-DRUG CONJUGATES THAT SPECIFICALLY BINDS TO LIPOPOLYSACCHARIDE AND USES THEREOF | VISTERRA INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-116459240-B | Application of KL-2 and derivatives thereof in preparation of antibacterial infection medicines | 华中科技大学协和深圳医院 | 2024-03-19 | — | — | CN | disclosed |
| US-11890319-B2 | Antibody molecule-drug conjugates and uses thereof | Visterra, Inc. (US) | 2024-02-06 | — | — | US | disclosed |
| US-6068972-A | SCREENING BY CONTACTING MICROORGANISMS WITH ORGANIC SOLVENT, DETERMINING EXPRESSION OF ACR-LIKE EFFLUX PUMP GENE LOCUS, COMPARING TO CONTROL, ALTERED EXPRESSION INDICATES ACTIVATION OF MULTIPLE ANTIBIOTIC RESISTANCE PHENOTYPE | TRUSTEES OF TUFTS COLLEGE (US) | 2000-05-30 | — | — | US | disclosed |
| US-5989832-A | Method for screening for non-tetracycline efflux pump inhibitors | MICROCIDE PHARMACEUTICALS, INC. (US) | 1999-11-23 | — | — | US | disclosed |
| WO-1999017791-A1 | METHODS AND COMPOSITIONS FOR REDUCING BACTERIAL TOLERANCE OF DISINFECTANTS AND ORGANIC SOLVENTS | TRUSTEES OF TUFTS COLLEGE (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999017607-A2 | METHODS AND COMPOSITIONS FOR REDUCING BACTERIAL TOLERANCE OF DISINFECTANTS AND ORGANIC SOLVENTS | TRUSTEES OF TUFTS COLLEGE (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0823942-A1 | EFFLUX PUMP INHIBITORS | Microcide Pharmaceuticals, Inc. (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996033285-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969476-B2 | Antibody molecule-drug conjugates and uses thereof | CD14, EPCAM, CD44 | NPY4R 4726/4885NPY1R 4837/4885NPY2R 4844/4885 |
| US-11890319-B2 | Antibody molecule-drug conjugates and uses thereof | CD14, EPCAM, CD44 | NPY4R 4726/4885NPY1R 4837/4885NPY2R 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.